Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
In 2025, some cities around the world have become home to the highest number of…
India is a country where many different types of fruits are grown because of its…
In a significant development amidst ongoing legal scrutiny, BlackRock, the world’s largest asset manager, has…
Union Minister of Health and Family Welfare, J.P. Nadda, recently launched the Inter-AIIMS Referral Portal…
India and Russia have agreed on six new strategic projects to bolster bilateral investment ties,…
The 9th edition of the Global Technology Summit (GTS), a flagship event co-hosted by the…